Tirzepatide for Weight Loss
The first dual-action GIP/GLP-1 medication, delivering the highest weight loss in clinical trials.
Medically reviewed by GlobalGLP1 Editorial Team • Updated April 2026 • Sources: FDA prescribing information, peer-reviewed clinical trials
Overview
Tirzepatide is a first-in-class dual GIP/GLP-1 receptor agonist developed by Eli Lilly. It uniquely targets both the GIP and GLP-1 receptors, producing greater weight loss and blood sugar control than GLP-1-only medications. Approved as Mounjaro for type 2 diabetes (2022) and Zepbound for weight management (2023), tirzepatide has shown weight loss of up to 22.5% in clinical trials — the highest of any GLP-1 class medication.
How Tirzepatide Works
Tirzepatide works through a dual mechanism: it activates both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 receptors. This dual action provides enhanced appetite suppression, improved insulin sensitivity, and greater metabolic effects compared to GLP-1-only drugs. The GIP receptor activation may contribute to improved fat metabolism and energy expenditure.
FDA Approvals
Mounjaro
Type 2 diabetes mellitus
2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg weekly injection
Zepbound
Chronic weight management
2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg weekly injection
Dosing & Administration
Gradual dose escalation over 20-24 weeks. Many patients achieve significant results at 10 mg without needing the full 15 mg dose. Your provider will adjust based on your response and side effects.
Weight Loss Efficacy
In the SURMOUNT-1 trial, participants on tirzepatide 15 mg lost an average of 22.5% of their body weight over 72 weeks. At the 10 mg dose, average weight loss was 21.4%. Over a third (36%) on the highest dose lost 25% or more of their body weight, and 63% lost 20% or more.
A1C Reduction: 1.9-2.6% A1C reduction (Mounjaro, for diabetes)
Side Effects
Common Side Effects
- Nausea (decreases over time)
- Diarrhea
- Decreased appetite
- Vomiting
- Constipation
- Abdominal pain
- Dyspepsia
- Injection site reactions
Serious (Rare)
- Pancreatitis (rare)
- Gallbladder disease
- Thyroid C-cell tumors (boxed warning, rodent studies)
- Hypoglycemia (with insulin or sulfonylureas)
- Severe GI events
- Allergic reactions including anaphylaxis
Managing side effects: Similar to semaglutide — slow dose escalation is key. Eating smaller, more frequent meals and avoiding high-fat foods helps manage GI effects. Contact your provider if vomiting is persistent or severe.
Cost & Savings
Savings programs: Eli Lilly offers the Zepbound Savings Card (commercially insured patients may pay as low as $25/month) and the LillyDirect platform for direct-to-patient delivery.
Who Should Not Take Tirzepatide
- Personal or family history of medullary thyroid carcinoma (MTC)
- Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
- Known hypersensitivity to tirzepatide
- Pregnancy or planning to become pregnant
- Severe gastrointestinal disease
Cardiovascular Effects
The SURPASS-CVOT trial (published NEJM late 2025) studied tirzepatide vs. dulaglutide in patients with type 2 diabetes and cardiovascular disease. Tirzepatide met noninferiority for MACE (HR 0.93) but did not achieve superiority. The expanded MACE endpoint (including revascularization) was significantly reduced (HR 0.88). Separately, the SUMMIT trial (2024) showed tirzepatide reduced the composite of cardiovascular death or worsening heart failure by 38% and heart failure hospitalization by 56% in patients with obesity and HFpEF.
What this means for you: Tirzepatide has confirmed cardiovascular safety comparable to dulaglutide. Its heart failure benefit in obesity is particularly notable — the SUMMIT trial demonstrated meaningful hard-endpoint reductions. Patients with both obesity and heart failure may especially benefit.
Timeline: What to Expect
Noticeable decrease in hunger and food noise. Some patients report reduced cravings for high-calorie foods specifically.
Consistent weight loss begins during dose escalation. Average 3-5% body weight lost. Dual GIP/GLP-1 action accelerates early results.
Approaching maintenance dose (10-15 mg). Steady 1-2.5 lbs per week loss. Blood sugar improvements prominent.
Average 15-20% body weight lost. Dramatic improvements in metabolic health markers, blood pressure, and lipids.
Weight loss plateau at 20-22.5% average. Some patients achieve 25%+ loss. Maintenance phase with sustained metabolic benefits.
Drug Interactions
Risk of severe hypoglycemia. Reduce insulin dose by 20-50% when initiating tirzepatide. Sulfonylurea dose reduction may also be needed.
Tirzepatide slows gastric emptying, potentially affecting absorption of oral drugs. Most significant during dose escalation when GI effects are strongest.
Monitor INR closely during initiation and dose changes. Delayed gastric emptying can alter warfarin absorption patterns.
Oral contraceptive effectiveness may be reduced during initial treatment. Consider non-oral contraception during the first 4 weeks of treatment and for 4 weeks after each dose increase.
Special Populations
Contraindicated. Discontinue at least 1 month before planned conception. Animal studies showed adverse developmental effects at high doses.
No dose adjustment for mild-to-moderate impairment. Limited data in severe renal impairment (eGFR <30). Monitor hydration closely as GI effects can impair kidney function.
No dose adjustment required for mild-to-moderate hepatic impairment. Not studied in severe hepatic impairment.
No dose adjustment needed. SURMOUNT trials included patients aged 65-75. Slower dose escalation may be appropriate to minimize GI effects.
Not yet FDA-approved for adolescents. Clinical trials in teens (SURMOUNT-TEENS) are underway. Off-label use is at the provider's discretion.
After Stopping Treatment
In the SURMOUNT-4 trial, participants who switched from tirzepatide to placebo after 36 weeks regained about 14% of body weight over the next 52 weeks — roughly two-thirds of their initial loss. Those who continued tirzepatide lost an additional 5.5%. This highlights the importance of continued treatment for maintaining results.
Mitigation strategies: Lifestyle modification during treatment is critical for durability. Some providers are exploring lower maintenance doses. Transition planning should begin well before discontinuation.
Frequently Asked Questions
Clinical trials suggest tirzepatide produces greater average weight loss (20-22.5%) compared to semaglutide (15-17%). However, individual responses vary. The SURPASS-2 trial directly compared Mounjaro to Ozempic and showed superior A1C reduction and weight loss with tirzepatide.
Both contain tirzepatide at the same doses. Mounjaro is FDA-approved for type 2 diabetes, while Zepbound is approved for chronic weight management. Your doctor will prescribe the appropriate one based on your diagnosis.
Appetite reduction typically begins within 1-2 weeks. Measurable weight loss usually starts after 4-8 weeks as doses escalate. Full weight loss effects develop over 12-18 months at the maintenance dose.
Yes. Zepbound is FDA-approved for weight management in adults with BMI 30+ or BMI 27+ with at least one weight-related condition, regardless of diabetes status.
Tirzepatide is the only dual GIP/GLP-1 receptor agonist. By targeting both receptors, it provides enhanced metabolic benefits that single-target GLP-1 medications like semaglutide don't offer. This dual mechanism is believed to contribute to its superior efficacy.
Long-term data (3+ years) is still being collected. The SURMOUNT trials showed sustained weight loss over 72 weeks with continued use. Like semaglutide, weight regain is expected after discontinuation. Cardiovascular outcome trials are ongoing.
Compare Tirzepatide providers by pricing, telehealth availability, and patient ratings.
Search Tirzepatide Clinics →Find Tirzepatide Clinics by State
Ready to start Tirzepatide?
Search our directory of 2,770 GLP-1 clinics. Filter by medication, insurance, and telehealth availability.
Medical Disclaimer: This guide is for informational purposes only and is not medical advice. All clinical data is sourced from FDA prescribing information and published peer-reviewed trials. Individual results vary. Always consult a qualified healthcare provider before starting, stopping, or switching any medication.